MedTrace Logo

Effects of LopiGLIK® on Cardiovascular Risk

NCT02898805 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2019-07-30

No results posted yet for this study

Summary

The study is designed to compare the effects of two combination of nutraceuticals: Armolipid Plus® and LopiGLIK® (Akademy Pharma), a new supplement that, in addition to Berberine and Red Rice, contains Morus Alba's extract. The study will analyze the impact of 16 week treatment with one of the combinations, according to a randomized scheme, on metabolic parameters in dyslipidemic subjects that do not require or not tolerate a statin therapy. In particular, it will assess the ability of the two combinations to reduce the levels of total and LDL cholesterol, HbA1C, glicaemia and insulin and increase those of HDL cholesterol.

Conditions

  • Cardiovascular Risk Factors

Interventions

OTHER

Placebo

OTHER

Prescribed Diet

DIETARY_SUPPLEMENT

LopiGLIK®

DIETARY_SUPPLEMENT

Armolipid Plus

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Bruno Trimarco, Professor · FEDERICO II UNIVERSITY - NAPLES

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-01-31
Completion
2018-12-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02898805 on ClinicalTrials.gov